Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma Statistics

Total Valuation

Nuvectis Pharma has a market cap or net worth of $290.32 million. The enterprise value is $265.06 million.

Market Cap	290.32M
Enterprise Value	265.06M

Important Dates

The last earnings date was Tuesday, May 5, 2026, before market open.

Earnings Date	May 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Nuvectis Pharma has 26.53 million shares outstanding. The number of shares has increased by 26.31% in one year.

Current Share Class	26.53M
Shares Outstanding	26.53M
Shares Change (YoY)	+26.31%
Shares Change (QoQ)	+0.94%
Owned by Insiders (%)	41.67%
Owned by Institutions (%)	18.29%
Float	15.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	19.83
P/TBV Ratio	20.41
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.27

Current Ratio	2.27
Quick Ratio	2.25
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -154.43% and return on invested capital (ROIC) is -100.45%.

Return on Equity (ROE)	-154.43%
Return on Assets (ROA)	-63.61%
Return on Invested Capital (ROIC)	-100.45%
Return on Capital Employed (ROCE)	-198.78%
Weighted Average Cost of Capital (WACC)	3.61%
Revenue Per Employee	n/a
Profits Per Employee	-$2.47M
Employee Count	12
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +2.72% in the last 52 weeks. The beta is -0.12, so Nuvectis Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.12
52-Week Price Change	+2.72%
50-Day Moving Average	9.00
200-Day Moving Average	7.61
Relative Strength Index (RSI)	58.51
Average Volume (20 Days)	108,689

Short Selling Information

The latest short interest is 1.46 million, so 5.52% of the outstanding shares have been sold short.

Short Interest	1.46M
Short Previous Month	1.54M
Short % of Shares Out	5.52%
Short % of Float	9.46%
Short Ratio (days to cover)	28.33

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-28.27M
Pretax Income	-27.16M
Net Income	-29.59M
EBITDA	n/a
EBIT	-28.27M
Earnings Per Share (EPS)	-$1.30

Balance Sheet

The company has $25.13 million in cash and n/a in debt, with a net cash position of $25.13 million or $0.95 per share.

Cash & Cash Equivalents	25.13M
Total Debt	n/a
Net Cash	25.13M
Net Cash Per Share	$0.95
Equity (Book Value)	14.22M
Book Value Per Share	0.54
Working Capital	14.22M

Cash Flow

Operating Cash Flow	-18.35M
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Nuvectis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-26.31%
Shareholder Yield	-26.31%
Earnings Yield	-10.20%
FCF Yield	n/a

Analyst Forecast

The average price target for Nuvectis Pharma is $16.80, which is 53.50% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$16.80
Price Target Difference	53.50%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1